Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today
There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learnin
Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.

3 Hot Penny Stocks To Watch Before Next Week

02:19pm, Wednesday, 07'th Jun 2023
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stock
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE